Monoclonal antibodies to growth factors and growth factor receptors: Their diagnostic and therapeutic potential in brain tumors

Journal of Neuro-Oncology

Volumn 35, Issue 3, 1997, Pages 259-273

  Ashley, David M ^a   Batra, Surinder K ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumors; Growth factors; Monoclonal antibodies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

BRAIN TUMOR; CLINICAL TRIAL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MAJOR CLINICAL STUDY; META ANALYSIS; ONCOGENE C ERB; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; GROWTH SUBSTANCES; HUMANS; RECEPTORS, GROWTH FACTOR;

EID: 0030806638     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005812417638     Document Type: Review

References (99)

1. Weiner HL: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 37: 179-93; discussion 193-4, 1995
2. FlemingTP, Saxena A, Clark WC, et al.: Amplification and/ or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-3, 1992
3. Maxwell M, Naber SP, Wolfe HJ, et al.: Coexpression of platelet-derived growth factor (PD GF) and PD GF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86: 131-40, 1990
4. Shamah SM, Stiles CD, Guha A: Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13: 7203-12, 1993
5. Lens PF, Altena B, Nusse R: Expression of c-sis and platelet-derived growth factor in in vitro-transformed glioma cells from rat brain tissue transplacentally treated with ethyl-nitrosourea. Mol Cell Biol 6: 3537-40, 1986
6. Kuratsu J, Ushio Y: Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro. J Neurosurg 73: 436-40, 1990
7. Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, Rizkalla WM: Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 51: 5760-5, 1991
8. Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, Rizkalla WM: Acidic and basic fibroblast growth factors are present in glioblastoma multiforme and normal brain. Ann NY A cad Sci 638: 477-80, 1991
9. Morrison RS, Gross JL, Herblin WF, et al.: Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res 50: 2524-9, 1990
10. Morrison RS, Yamaguchi F, Bruner JM, Tang M, McKeehan W, Berger MS: Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 54: 2794-9, 1994
11. Gammeltoft S, Ballotti R, Kowalski A, Westermark B, Van Obberghen E: Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res 48: 1233-7, 1988
12. Glick RP, Gettleman R, Patel K, Lakshman R, Tsibris JC: Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects. Neurosurgery 24: 791-7, 1989
13. Merrill MJ, Edwards NA : Insulin-like growth factor-I receptors in human glial tumors. J Clin Endocrinol Metab 71: 199-209, 1990
14. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-7, 1993
15. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL: Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91: 12867-71, 1994
16. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328: 847-54, 1993
17. Bigner DD, Brown M, Coleman RE, et al.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2 - a preliminary report. J Neurooncol 24: 109-22, 1995
18. Zalutsky MR, Moseley RP, Coakham HP, Coleman RE, Bigner DD: Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49: 2807-13, 1989
19. Zalutsky MR, Moseley RP, Benjamin RC et al: Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50: 4105-10, 1990
20. Buchsbaum DJ: Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 55: 5729s-5732s, 1995
21. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: Modeling analysis of the global and microscopic distribution of immunoglobulin G , F(ab')2, and Fab in tumors. Cancer Res49: 5656-63, 1989
22. Fujimori K, Fisher DR, Weinstein JN: Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. Cancer Res 51: 4821-7, 1991
23. Langmuir VK, Mendonca HL, Woo DV: Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 52: 4728-34, 1992
24. Wargalla UC, Reisfeld RA : Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci USA 86: 5146-50, 1989
25. B ender H, Takahashi H, Adachi K, et al.: Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 52: 121-6, 1992
26. Reist CJ, Archer GE, Kurpad SN, et al.: Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55: 4375-82, 1995
27. Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. A method for the radiohalogenation of internalizing antibodies. Society of Nuclear Medicine Annual Meeting J Nucl Med, 1996
28. Reist CJ, Archer GE, Garg PK, Bigner DD, Zalutsky MR. N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC) radiolabeling enhances tumor retention of an internalizing monoclonal antibody. AACR Procedings, National Meeting, 1996
29. Ali SA, Warren SD, Richter KY, et al.: Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts. Cancer Res 50: 783s-788s, 1990
30. Schuster JM, Bigner DD : Immunotherapy and monoclonal antibody therapies. Curr Opin Oncol 4: 547-52, 1992
31. Yokota T, Milenic De, Whitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-8, 1992
32. Yokota T, Milenic De, Whitlow M, Wood Jf, Hubert SI, Schlom J : Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 53: 3776-83, 1993
33. Fan Z, Masui H, Altas I, Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53: 4322-8, 1993
34. Colapinto EV, Humphrey PA, Zalutsky MR, et al.: Comparative localization of murine monoclonal antibody Mel-14 F (ab')2 fragment and whole IgG2a in human glioma xenografts. Cancer Res 48: 5701-7, 1988
35. Bullard DE, Wikstrand CJ, Humphrey PA, et al.: Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). Nuklearmedizin 25: 210-5, 1986
36. Pastan IH, Archer GE, McLendon RE, et al.: Intrathecal administration of single-chain immunotoxin, LMB-7 [B 3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci USA 92: 2765-9, 1995
37. Riva P, Arista A, Franceschi G, et al.: Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55: 5952s-5956s, 1995
38. Moseley RP, Papanastassiou V, Zalutsky MR, et al.: Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 52: 38-43, 1992
39. Moseley Rp, Davies Ag, Richardson R b, et al.: Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Brit J Cancer 62: 637-42, 1990
40. Papanastassiou V, Pizer BL, Chandler CL, Zananiri TF, Kemshead JT, Hopkins KI: Pharmacokinetics and dose estimates following intrathecal administration of 131I-monoclonal antibodies for the treatment of central nervous system malignancies. Int J Radiat Oncol Biol Phys 31: 541-52, 1995
41. Brown MT, Coleman RE, Friedman AH, et al.: Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomenigeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase 1 trial results. Clin Can Res, in press: 1996
42. Brown MT, Coleman RE, Friedman AH, et al. Phase 1 studies 131I-81C6 mAb for recurrent cystic gliomas or brain tumor resection cavities. Society of Neuro-Oncology. Santa Fe USA, 1996: sA437
43. Hiesiger EM, Hayes RL, Pierz DM, Budzilovich G N: Prognostic relevance of epidermal growth factor receptor (E G F-R) and c-neu/erbB2 expression in glioblastomas (G B Ms). J Neurooncol 16: 93-104, 1993
44. Coussens L, Yang-Feng TL, Liao YC, et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-9, 1985
45. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ: Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71: 473-7, 1995
46. Batra SK, Rasheed BK, Bigner SH, Bigner DD : Oncogenes and anti-oncogenes in human central nervous system tumors. Lab Invest 71: 621-37, 1994
47. Bigner SH, Burger PC, Wong AJ, et al.: Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol 47: 191-205, 1988
48. Bigner SH, Humphrey PA, Wong AJ, et al.: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50: 8017-22, 1990
49. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-903, 1987
50. Wikstrand CJ, Hale LP, Batra SK, et al.: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55 3140-8, 1995
51. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner D D : Tumor antigens in astrocytic gliomas. Glia 15: 244-56, 1995
52. Humphrey PA, Wong AJ, Vogelstein B, et al.: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48: 2231-8, 1988
53. Humphrey PA, Wong AJ, Vogelstein B, et al.: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87: 4207-11, 1990
54. Humphrey PA, Gangarosa LM, Wong AJ, et al.: Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 178: 1413-20, 1991
55. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al.: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Diff 6: 1251-1259, 1995
56. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M: A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn J Cancer Res 81: 773-9, 1990
57. Nishikawa R, Ji XD, Harmon RC, et al.: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727-31, 1994
58. Ekstrand AJ, Longo N, Hamid ML, et al.: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9: 2313-20, 1994
59. Baselga J, Mendelsohn J: Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64: 127-54, 1994
60. Wen D, Peles E, Cupples R, et al.: Neu differentiation factor: a transmembrane glycoprotein containing an E G F domain and an immunoglobulin homology unit. Cell 69: 559-72, 1992
61. Peles E, Bacus SS, Koski RA, et al.: Isolation of the neu/ HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205-16, 1992
62. Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49: 6237-41, 1989
63. Arteaga CL, Kitten LJ, Coronado EB, et al.: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418-23, 1989
64. Kim KJ, Li B, Houck K, Winer J, Ferrara N: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7: 53-64, 1992
65. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 697-706, 1985
66. Drebin JA, Link VC, Weinberg RA, Greene MI: Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83: 9129-33, 1986
67. Baselga J, Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29: 127-38, 1994
68. Mendelsohn J, Masui H, Goldenberg A: Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway. Trans Assoc Am Physicians 100: 173-8, 1987
69. Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. J Steroid Biochem Mol Biol 37: 889-92, 1990
70. Mendelsohn J: The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol 1: 339-44, 1990
71. Mendelsohn J: Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Monogr Natl Cancer Inst: 125-31, 1992
72. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD : Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50: 6039-44, 1990
73. Rodeck U, Herlyn M, Koprowski H: Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem 35: 315-20, 1987
74. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DD, Pastan I: Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Can Res 1: 859-864, 1995
75. Kim KJ, Li B, Winer J, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-4, 1993
76. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I: A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD 16. Cancer Res 53: 94-100, 1993
77. Masui H, Moroyama T, Mendelsohn J: Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 46: 5592-8, 1986
78. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-42, 1993
79. Baselga J, Norton L, Masui H, et al.: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-33, 1993
80. Gutowski MC, Briggs SL, Johnson DA: Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates. Cancer Res 51: 5471-5, 1991
81. Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J: Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 49: 3482-8, 1989
82. Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H: Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medullo-blastoma xenografts in athymic mice. Cancer Res 54: 1008-15, 1994
83. Weiner LM, Clark JI, Ring DB, Alpaugh RK: Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 4: 453-6, 1995
84. Weiner LM, Clark JI, Davey M, et al.: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 55: 4586-93, 1995
85. Miyamoto CT, Woo DV, Rackover MA, Brady LW, Steplewski Z. The adjuvant use of 1-125 radiolabelled EGF-425 in the treatment of intracranial tumors. Third conference on radioimmunodetection and radioimmunotherapy of cancer. Princeton N.J. U.S.A: American college of radiology, 1990
86. Brady LW, Markoe AM, Woo DV, et al.: Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot study. J Neurosurg Sci 34: 243-9, 1990
87. Kalofonos HP, Pawlikowska TR, Hemingway A, et al.: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30: 1636-45, 1989
88. Bigner SH, Vogelstein B, Mark J, Friedman HS, Bigner DD: Cytogenetics and molecular genetics: their status and role in understanding the behavior of central nervous system neoplasms. Monogr Pathol: 30-40, 1990
89. Jaros E, Perry RH, Adam L, et al.: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66: 373-85, 1992
90. Arita N, Hayakawa T, Izumoto S, et al.: Epidermal growth factor receptor in human glioma. J Neurosurg 70: 916-9, 1989
91. Libermann TA, Nusbaum HR, Razon N, et al.: Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl 3: 161-72, 1985
92. Batra SK, Niswonger ML, Wikstrand CJ, et al.: Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma 13: 87-97, 1994
93. He X, Archer GE, Wikstrand CJ, et al.: Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol 52: 127-37, 1994
94. Slavin-Chiorini DC, Horan Hand PH, Kashmiri SV, Calvo B, Zaremba S, Schlom J: Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 53: 97-103, 1993
95. Adams GP, McCartney JE, Tai MS, et al.: Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53: 4026-34, 1993
96. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U SA 91: 2076-80, 1994
97. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021-9, 1995
98. Viola JJ, Agbaria R, Walbridge S, et al.: In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res 55: 1306-9, 1995
99. LoBuglio AF, Wheeler RH, Trang J, et al.: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86: 4220-4, 1989